Macrophage FOXO1 Inhibition Protects Against Hyperglycaemia‐Associated Kidney Injury
Basic & Clinical Pharmacology & Toxicology · 2026-10 · 139 (4)
DOI: 10.1111/bcpt.70296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 03.09.2026. Verfasst von Hejie Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Xinjiang Medical University, Key Laboratory of Natural Medicine Activity Components and Drug Release …. Hauptthemen laut MEDLINE: Forkhead Box Protein O1, Macrophages, Diabetic Nephropathies, Diabetes Mellitus, Experimental. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Key Research and Development Project of Xinjiang Uygur Autonomous Region.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is one of the most significant microvascular complications of diabetes, characterized by high incidence and mortality; however, its pathogenesis remains unclear. Renal inflammation and macrophage infiltration play pivotal roles in driving DKD progression. The transcription factor forkhead box protein O1 (FOXO1) regulates the transcriptional expression of multiple pro‐inflammatory molecules and modulates macrophage polarization. Nevertheless, its specific role in DKD macrophages remains unknown. In vivo, streptozotocin‐induced DKD mice showed significantly higher FOXO1 expression in infiltrated kidney macrophages. Treatment with the FOXO1‐selective inhibitor AS1842856 for 4 or 12 weeks reduced serum creatinine, blood urea nitrogen, renal matrix collagen deposition and the severity of macrophage infiltration in DKD mice. In vitro, using mouse bone marrow–derived macrophages and RAW264.7 cells cultured under high glucose, we found that high glucose promoted pro‐inflammatory M1 macrophage polarization. This polarization process was effectively blocked by either AS1842856 treatment or FOXO1 small interfering RNA‐mediated gene silencing. In summary, FOXO1 critically regulates macrophage infiltration and functional phenotype in DKD‐affected renal tissue. Targeting FOXO1 therefore holds promise as a potential therapeutic strategy to delay DKD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Xinjiang Medical University, Key Laboratory of Natural Medicine Activity Components and Drug Release Technology in Xinjiang, Key Laboratory of the Ministry of Education in…
- Department of Pharmacology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
- Department of Wound Healing Center and Interventional Radiology and Vascular Surgery, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Ying Zhang, Linlin Li, Lu Tie
Förderung
- National Natural Science Foundation of China
- Key Research and Development Project of Xinjiang Uygur Autonomous Region
Zitieren
APA
Zhu, H., Liu, Q., Yang, L., Zhang, C., Zhang, Y., Zhao, R., Zheng, Z., Wang, X., Li, L., Zhang, L., & Tie, L. (2026). Macrophage FOXO1 Inhibition Protects Against Hyperglycaemia‐Associated Kidney Injury. Basic & Clinical Pharmacology & Toxicology, 139(4). https://doi.org/10.1111/bcpt.70296
Vancouver
Zhu H, Liu Q, Yang L, Zhang C, Zhang Y, Zhao R, et al. Macrophage FOXO1 Inhibition Protects Against Hyperglycaemia‐Associated Kidney Injury. Basic & Clinical Pharmacology & Toxicology. 2026;139(4). doi:10.1111/bcpt.70296
BibTeX
@article{Zhu2026,
author = {Zhu, Hejie and Liu, Qian and Yang, Lunqiang and Zhang, Chenyu and Zhang, Ying and Zhao, Ruiqi and Zheng, Zhongyuan and Wang, Xi and Li, Linlin and Zhang, Long and Tie, Lu},
title = {Macrophage FOXO1 Inhibition Protects Against Hyperglycaemia‐Associated Kidney Injury},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {139},
number = {4},
doi = {10.1111/bcpt.70296}
}
EUVIMED